

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 April 2025 (10.04.2025)



(10) International Publication Number
WO 2025/073002 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 47/26 (2006.01)
A61K 9/00 (2006.01) A61K 47/36 (2006.01)
A61K 9/20 (2006.01) A61K 47/38 (2006.01)
A61K 47/02 (2006.01)

901, Level 9, 109 Pitt Street, Sydney, New South Wales
2000 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Mel-
bourne, Victoria 3000 (AU).

(21) International Application Number:

PCT/AU2024/051042

(22) International Filing Date:

03 October 2024 (03.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023903165 03 October 2023 (03.10.2023) AU

(71) Applicant: **ACTINOGEN MEDICAL LIMITED**

[AU/AU]; Suite 901, Level 9, 109 Pitt Street, Sydney, New
South Wales 2000 (AU).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TABLET FORMULATION




Figure 1

(57) Abstract: Xanamem, also known as UE2343, is an effective inhibitor of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1). Due to its inhibitory action, Xanamem has been proposed as a treatment of disorders that are ameliorated by the inhibition of 11 β -HSD1, such as metabolic syndrome, cardiovascular disorders, and CNS disorders. The present 5 disclosure relates to the formulation of Xanamem and excipients, particularly lactose and microcrystalline cellulose, as immediate-release tablet formulations.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE